FOHAIC-1
Regimen
- Experimental
- HAIC FOLFOX (oxaliplatin + 5-FU)
- Control
- sorafenib
Population
Advanced hepatocellular carcinoma, predominantly with macrovascular invasion or extrahepatic spread (Chinese multicentre)
Key finding
mOS 13.9 vs 8.2 mo (HR 0.41, P<0.001) — HAIC-FOLFOX beats sorafenib head-to-head in advanced HCC. Biomarkers ATP7A/B identified.
Source: PMID 34905388